Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification

Vaccinology: Principles and Practice

Volumn , Issue , 2012, Pages 452-463

  Rees, Robert ^a   Laversin, Stephanie ^a   Murray, Cliff ^b   Ball, Graham ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b Source BioScience   (United Kingdom)

Author keywords

Bioinformatics; Biomarkers; Breast cancer; Genomics; Patient stratification; Personalized medicine; Proteomics

Indexed keywords

EID: 84886119344     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118345313.ch30     Document Type: Chapter

References (62)

1. FDA. Critical Path Opportunities Report, March 2006. Available at www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf. Accessed Feb 2012.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98(19):10869-74.
3. Caldas C, Aparicio SA. The molecular outlook. Nature 2002;415(6871):484-5.
4. Ponder BA. Inherited predisposition to breast cancer. Biochem Soc Symp 1998;63:223-30.
5. Ellisen LW, Haber DA. Hereditary breast cancer. Annu Rev Med 1998;49:425-36.
6. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266(5182): 66-71.
7. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378(6559):789-92.
8. Greene MH. Genetics of breast cancer. Mayo Clin Proc 1997;72(1):54-65.
9. Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol 2002; 44(2):121-41.
10. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003;3(5):573-85.
11. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21(35): 5462-82.
12. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol 2007;34(2 Suppl 3):S10-16.
13. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797):747-52.
14. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100(14):8418-23.
15. Abd El-Rehim DM, Ball G, Pinder SE, et al. Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116(3):340-50.
16. Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008;98(1):137-42.
17. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45(3):361-6.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41(3A): 154-61.
19. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22(3):207-19.
20. O'Brien N, Maguire TM, O'Donovan N, et al. Mammaglobin a: a promising marker for breast cancer. Clin Chem 2002;48(8):1362-4.
21. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep- CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356(9246):1981-2.
22. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 1995;34(4): 499-504.
23. Borstnar S, Vrhovec I, Svetic B, Cufer T. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer 2002;3(2):138-46.
24. Foekens JA, Kos J, Peters HA, et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998;16(3):1013-21.
25. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999- 2009.
26. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-36.
27. Lancashire LJ, Lemetre C, Ball GR. An introduction to artificial neural networks in bioinformatics - application to complex microarray and mass spectrometry datasets in cancer studies. Brief Bioinform 2009;10(3):315-29.
28. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164(1):35-42.
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26.
30. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61(14): 5407-14.
31. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81(1):54-61.
32. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005;16(Suppl 4):iv14-19.
33. Cristofanilli M, Hortobagyi GN. Molecular targets in breast cancer: current status and future directions. Endocr Relat Cancer 2002;9(4):249-66.
34. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62(1):209-43.
35. Holmes FA, Fritsche HA, Loewy JW, et al. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol 1990;8(6): 1025-35.
36. Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973;1(5844):13-14.
37. Wishart GC, Gaston M, Poultsidis AA, Purushotham AD. Hormone receptor status in primary breast cancer - time for a consensus? Eur J Cancer 2002; 38(9):1201-3.
38. Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer 2002;3(4):281-7.
39. Liu TJ, el-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995;5(14):3117-22.
40. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991;20(1):11-17.
41. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1(4):703-18.
42. Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005;15(4):319-26.
43. Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem Cytochem 1998; 46(11):1335-7.
44. Wu K, Zhang Y, Xu XC, et al. The retinoid X receptorselective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62(22): 6376-80.
45. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A. The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 2001;114(Pt 22):4117-26.
46. Castelli C, Rivoltini L, Rini F, et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2004;53(3):227-33.
47. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92.
48. Irvin WJ, Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008;44(18):2799-805.
49. Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOFMS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005;14(4): 250-55.
50. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005;1(1):37-50.
51. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19(16):3660-68.
52. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362(9381):362-9.
53. Esteban J, Baker J, Cronin M, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue [abstract]. Proc Am Soc Clin Oncol 2003;22:A3416.
54. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274(5289): 998-1001.
55. Laronga C, Drake RR. Proteomic approach to breast cancer. Cancer Control 2007;14(4):360-68.
56. Garrisi VM, Abbate I, Quaranta M, et al. SELDI-TOF serum proteomics and breast cancer: which perspective? Expert Rev Proteomics 2008;5(6):779-85.
57. Matharoo-Ball B, Ratcliff L, Lancashire L, et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/ bioinformatic approach. Proteomics Clin Appl 2007; 1(6):605-20.
58. Lemetre C, Lancashire L, Rees RC, Ball GR. Artificial neural network based algorithm for biomolecular interactions modeling. IWANN 2009;1:877-85.
59. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98(20):11462-7.
60. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11(12):4469-78.
61. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-79.
62. Menard C, Ghiringhelli F, Roux S, et al. CTLA-4 blockade confers lymphocyte resistance to regulatory Tcells in advanced melanoma: surrogate mark efficacy of tremelimumab? Clinical Cancer Res 2008;14:5242-9.